ARDEN HILLS, Minn.--(BUSINESS WIRE)--IntriCon Corporation (NASDAQ:IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced financial results for its first quarter ended March 31, 2014.
First Quarter Highlights:
- Net sales of $17.3 million represented the strongest quarter in more than five years;
- Gross margins of 27.6 percent rose from 25.5 percent in the sequential 2013 fourth quarter and 26.7 percent in the prior-year period;
- IntriCon achieved income from continuing operations of $787,000, a significant increase from $135,000 in the sequential 2013 fourth-quarter and a net loss of $23,000 in the prior year period;
- The company reduced bank debt $962,000 during the first quarter, and;
- Significant progress was made in building infrastructure to support IntriCon’s value hearing health initiatives.
First-Quarter Financial Results
For the 2014 first quarter, the company reported net sales of $17.3 million, a 22.5 percent increase from $14.1 million in the prior-year period. IntriCon had net income of $517,000, or $0.09 per diluted share, compared to a net loss of $471,000, or $0.08 per diluted share, for the 2013 first quarter.
The company reported net income from continuing operations of $787,000, or $0.14 per diluted share, in the 2014 first quarter versus a net loss of $23,000, or $0.00 per diluted share, in the prior-year period. Results from discontinued operations in the 2014 first quarter were a net loss of $270,000, or $0.05 per diluted share, versus a net loss of $448,000, or $0.08 per diluted share, in the prior-year period. Included in the 2014 first-quarter discontinued operations net loss was a loss of $120,000, or $0.02 per diluted share, from the sale of IntriCon Tibbetts Corporation, the company’s wholly owned subsidiary based in Camden, Maine.
“We are very pleased with our first-quarter performance—we delivered double-digit top-line gains across all of our businesses and returned to profitability,” said Mark S. Gorder, president and chief executive officer of IntriCon. “With our restructuring plan behind us and its significant cost reductions, we’re focused on driving business with our key medical and hearing health customers, and pursuing our highest potential growth opportunities: value hearing health and medical biotelemetry.
“For the third consecutive quarter we recorded sequential growth in sales, gross profit margins and profitability from continuing operations. Once again, the strong rise in our medical business stemmed from the continuing ramp of Medtronic’s 530G insulin pump system. Additionally, we saw increased order activity from hi HealthInnovations, and we anticipate measured increases for the remainder of the year to meet demand.”
Gross profit margins increased to 27.6 percent from 26.7 percent for the prior-year first quarter, and also rose sequentially from 25.5 percent in the 2013 fourth quarter. The gains were primarily due to volume increases and cost reductions generated from the global restructuring plan, partially offset by a less favorable sales mix.
Sales in IntriCon’s medical business rose 33 percent in the 2014 first quarter compared to the year-ago period. As previously disclosed, IntriCon’s largest customer, Medtronic, received FDA approval for their MiniMed 530G insulin pump in September 2013. IntriCon expects medical sales to remain strong in 2014 as Medtronic fulfills marketplace demand for the MiniMed 530G.
Hearing health sales also grew during the quarter, rising 12 percent from the prior-year quarter chiefly due to strong device sales, including those into the personal sound amplifier products (PSAP) channel. Additionally, the company saw solid growth in hearing aid device sales to hi HealthInnovations.
Said Gorder, “As we’ve noted previously, sales growth within the conventional hearing health channel continues to be hampered by high device costs, distribution inconveniences and retail consolidation. We believe that there’s significant opportunity in alternative care models such as the value hearing aid channel and PSAP channel. And to capitalize on these opportunities, we continue to concentrate efforts in the value hearing health space and we’re aggressively pursuing larger customers.”
Professional audio sales rose 12 percent from the prior-year period. IntriCon will continue to leverage its core technology in professional audio to support existing customers, as well as pursue related hearing health and medical product opportunities.
Concluded Gorder, “With a return to profitability and a favorable outlook from our major customers, we’re on track to continue to deliver strong performance in 2014. Our targeted focus going forward is aggressively driving our two largest growth opportunities: value hearing health and medical biotelemetry. Over the coming months, we will continue to build the necessary infrastructure to support our value hearing health initiative, ultimately positioning IntriCon to secure large opportunities in the marketplace.”
Conference Call Today
As previously announced, the company will hold an investment community conference call today, Monday, April 21, 2014, beginning at 4:00 p.m. CT. Mark Gorder, president and chief executive officer, and Scott Longval, chief financial officer, will review first-quarter performance and discuss the company’s strategies. To join the conference call, dial: 1-888-523-1225 and provide the conference ID number 9707055 to the operator.
A replay of the conference call will be available three hours after the call ends through 7:00 p.m. CT on Monday, May 5, 2014. To access the replay, dial 1-888-203-1112 and enter passcode: 9707055.
About IntriCon Corporation
Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature and micro-miniature body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better connected devices. IntriCon has facilities in the United States, Asia and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about IntriCon, visit www.intricon.com.
Statements made in this release and in IntriCon’s other public filings and releases that are not historical facts or that include forward-looking terminology are “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be affected by known and unknown risks, uncertainties and other factors that are beyond IntriCon’s control, and may cause IntriCon’s actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and other factors are detailed from time to time in the company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2013. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.
|Consolidated Condensed Statements of Operations|
|(In Thousands, Except Per Share Amounts)|
|Three Months Ended|
|March 31,||March 31,|
|Cost of sales||12,537||10,357|
|Sales and marketing||1,007||892|
|General and administrative||1,624||1,560|
|Research and development||1,168||1,229|
|Total operating expenses||3,882||3,681|
|Equity in (loss) of partnerships||(49||)||(58||)|
|Income (loss) from continuing operations before income taxes and discontinued operations||813||(33||)|
|Income tax expense||26||(10||)|
|Income (loss) before discontinued operations||787||(23||)|
|Loss on sale of discontinued operations||(120||)||-|
|Loss from discontinued operations, net of income taxes||(150||)||(448||)|
|Net income (loss)||$||517||$||(471||)|
|Basic income (loss) per share:|
|Net income (loss) per share:||$||0.09||$||(0.08||)|
|Diluted income (loss) per share:|
|Net income (loss) per share:||$||0.09||$||(0.08||)|
|Average shares outstanding:|
|Consolidated Condensed Balance Sheets|
|(In Thousands, Except Per Share Amounts)|
|March 31,||December 31,|
|Accounts receivable, less allowance for doubtful accounts of $124 at March 31, 2014 and $124 at December 31, 2013||6,529||5,433|
|Other current assets||1,064||1,337|
|Current assets of discontinued operations||-||382|
|Total current assets||18,546||17,337|
|Machinery and equipment||34,130||33,971|
|Less: Accumulated depreciation||29,680||29,232|
|Net machinery and equipment||4,450||4,739|
|Investment in partnerships||533||569|
|Other assets, net||668||749|
|Other assets of discontinued operations||-||132|
|Checks written in excess of cash||$||457||$||279|
|Current maturities of long-term debt||2,312||2,210|
|Accrued salaries, wages and commissions||2,117||1,676|
|Other accrued liabilities||1,920||1,893|
|Liabilities of discontinued operations||-||154|
|Total current liabilities||12,497||11,359|
|Long-term debt, less current maturities||5,207||6,271|
|Other postretirement benefit obligations||519||531|
|Accrued pension liabilities||815||839|
|Other long-term liabilities||205||247|
|Commitments and contingencies|
|Common stock, $1.00 par value per share; 20,000 shares authorized; 5,738 and 5,727 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively||5,738||5,727|
|Additional paid-in capital||16,588||16,434|
|Accumulated other comprehensive loss||(311||)||(331||)|
|Total shareholders' equity||14,010||13,308|
|Total liabilities and shareholders’ equity||$||33,391||$||32,720|